SCHEMBL7228152

SCHEMBL7228152

O=C(Oc1c[c]ccc1)N1CCCC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
POLB P06746 1/20 0.61
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
LMNA P02545 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
NPC1 O15118 4/20 0.53
MAPT P10636 3/20 0.51
HTT P42858 2/20 0.51
GAA P10253 3/20 0.50
TSHR P16473 2/20 0.50
RAB9A P51151 3/20 0.49
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MGLL Q99685 1/20 0.44
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385489 0.86 KMT2A (0.58) SMN1; SMN2MEN1KMT2ANPSR1NPC1
SCHEMBL1578826 0.80 ALDH1A1 (0.78) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL7226854 0.79 ALDH1A1 (0.75) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL11480252 0.79 ALDH1A1 (0.81) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL6882525 0.79 ALDH1A1 (0.81) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL3160001 0.78 KMT2A (0.58) ALDH1A1POLBMEN1KMT2ALMNA
SCHEMBL3175249 0.77 HPGD (0.57) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL3077817 0.77 SMN1; SMN2 (0.72) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL4914120 0.76 MEN1 (0.54) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL3154775 0.75 RAB9A (0.68) ALDH1A1POLBSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645939-B1 Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment MERCK & CO., INC. 2003-11-11 US claimed
US-6645939-B1 Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment MERCK & CO., INC. 2003-11-11 US disclosed
EP-1034164-A4 SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS MERCK & CO INC (US) 2001-07-11 EP disclosed
EP-1034164-A1 SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS Merck & Co., Inc. (US) 2000-09-13 EP disclosed
WO-1999026921-A1 SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1999-06-03 WO disclosed